Vanda Pharmaceuticals announced that the U.S. FDA has approved the Investigational New Drug application to evaluate VTR-297 for the treatment of onychomycosis. Onychomycosis, or tinea unguium, is a fungal infection of the nail.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VNDA:
- Court orders FDA to resolve Vanda Pharmaceuticals’ hearing request on HETLIOZ
- Vanda Pharmaceuticals announces U.S. patent allowance for Ponvory
- Vanda announces publication of journal article on Tradipitant study
- Vanda Pharmaceuticals’ IND application for VCA-894A granted FDA approval
- Vanda Pharmaceuticals says court denied in part U.S. motion to dismiss